The Interplay of IVD and Vaccines

Worthy of note. We’ve published reports on in vitro diagnostics and vaccines two months a part. And the two markets are not unrelated. Testing procedure volumes will relate, usually, to the occurrence of disease. Vaccines are intended to prevent disease. (Tests perform that function as well, by suggesting isolation or treatment of patients, but vaccines […]

Decline of Microarrays as RNA Sequencing Technology Surges: Report

The total RNA sequencing market was estimated at $2,368 million ($2.37 billion) in 2021, with roughly 3/4 of revenues from consumables. The following table and graph present the estimates for 2021. This according to a new report from Kalorama Information on RNA Sequencing markets. The sequencing market has continued to provide powerful tools that hold […]

The Market for the Making of IVD Products is 15 Billion: Report

The global in vitro diagnostic (IVD) industry incorporates a sizable contract manufacturing segment that supplies a full range of reagents and test kits, instruments and systems, and testing accessories. This according to Kalorama Information’s latest report on Contract Manufacturing in IVD: https://kaloramainformation.com/product/the-market-for-contract-manufacturing-in-in-vitro-diagnostics-ivd/. The market will grow at double the rate of the overall IVD market, […]

This Week in Cell and Gene Therapy: 11 New Developments to Know (September 12, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Kite Pharma, a Gilead Company based in Santa Monica, CA, has announced that the European Commission (EC) has granted approval for its chimeric antigen receptor (CAR) T cell therapy Tecartus […]

BCMOs: Who’s Winning?

The global BCMO industry is highly fragmented, with 40 BCMOs/CDMOs accounting for roughly one quarter of the industry’s revenues and the remainder comprised of a large number of smaller players. Based upon 2021 figures, Catalent led the overall market with estimated BCMO sales of $2.2 billion It was followed closely by Cytiva with $2.0 billion […]

CMOs Thrive on New Trend: Pharma Personnel Shortages

Biotechnology BCMO services, including both clinical and commercial production, were estimated at $11.9 billion in 2021. This according to the just-published Kalorama market analysis of the BCMO market. – https://kaloramainformation.com/product/biopharmaceutical-contract-manufacturing-organization-cmo-market-2022/ This segment has been expanding strongly by an estimated 13% per year since 2016, with increased growth of 15.5% per year from 2021 to 2026. […]

What Will Be the Next Emerging Disease Requiring IVDs?

Kalorama estimates a $3.7 billion market for emerging diseases. This market is expected to grow to $4.9 billion in 2026. This is based on it’s latest report: Emerging Infectious Disease Market, released August 2022: https://kaloramainformation.com/product/emerging-infectious-disease-diagnostics-markets-and-trends-2022/ In 2015 the World Health Organization held a workshop on prioritization of pathogens “for accelerated R&D for severe emerging diseases […]

127.4 Billion-Dollar IVD Market Blooms

Abbott Leads, Roche Close Second. COVID -19 Tests Largest Share, But Growth Comes from non-COVID The world in vitro diagnostic (IVD) market will reach $127.4 billion dollars in 2022, according to LabPulse.com’s sister publication Kalorama Information.  That’s the finding from the firm’s market research report, The Worldwide Market for In Vitro Diagnostics, 15th edition.  REPORT: […]

This Week in Cell and Gene Therapy: 8 New Developments to Know (August 22, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Prescient Therapeutics, a clinical stage oncology company based in Melbourne, Australia, has signed a five-year manufacturing agreement with Q-Gen Cell Therapeutics, a specialist cell therapy manufacturer based at the QIMR […]

American College of Physicians Discourages DTC Genetic Testing

A recent article in the ACP journal discourages the use of DTC genetic testing and recommends that testing be undertaken in the context of a patient-physician relationship with appropriate counseling. Physicians, healthcare systems, and others with access to patient data must safeguard the privacy, confidentiality, and security of patient information, including genomic information, ACP noted. […]